Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Ibuprofen 200mg modified-release capsules
1001010J0AABABA
|
Ibuprofen (NSAID) | Ibuprofen | Musculoskeletal and Joint Diseases | 18 |
|
Ibuprofen Twelve Plus Pain Relief 200mg/5ml oral suspension
1001010J0DKAABR
|
Ibuprofen Plus Pain Relief | Ibuprofen | Musculoskeletal and Joint Diseases | 18 |
|
Pyridostigmine bromide 60mg/5ml oral suspension
1002010Q0AABIBI
|
Pyridostigmine bromide | Pyridostigmine bromide | Musculoskeletal and Joint Diseases | 18 |
|
Pyridostigmine bromide 50mg/5ml oral suspension
1002010Q0AABJBJ
|
Pyridostigmine bromide | Pyridostigmine bromide | Musculoskeletal and Joint Diseases | 17 |
|
Stirlescent 250mg effervescent tablets
1001010P0BXAABD
|
Stirlescent | Naproxen | Musculoskeletal and Joint Diseases | 17 |
|
Tizagelan 4mg tablets
1002020T0BDABAA
|
Tizagelan | Tizanidine hydrochloride | Musculoskeletal and Joint Diseases | 17 |
|
Benzbromarone 50mg tablets
1001040A0AAABAB
|
Benzbromarone | Benzbromarone | Musculoskeletal and Joint Diseases | 16 |
|
Ibuprofen 200mg / Pseudoephedrine hydrochloride 30mg tablets
1001010J0AABJBJ
|
Ibuprofen (NSAID) | Ibuprofen | Musculoskeletal and Joint Diseases | 16 |
|
Hydroxychloroquine 200mg/5ml oral solution
1001030C0AAAIAI
|
Hydroxychloroquine sulfate | Hydroxychloroquine sulfate | Musculoskeletal and Joint Diseases | 15 |
|
Otezla 30mg tablets
1001030AABBAAAA
|
Otezla | Apremilast | Musculoskeletal and Joint Diseases | 15 |
|
Methofill 22.5mg/0.45ml inj pre-filled syringes
1001030U0BGAQBM
|
Methofill (Rheumatism) | Methotrexate | Musculoskeletal and Joint Diseases | 14 |
|
Myopridin 3mg tablets
1002020Z0BBAAAA
|
Myopridin | Pridinol mesilate | Musculoskeletal and Joint Diseases | 14 |
|
Allopurinol 300mg/5ml oral solution
1001040C0AAALAL
|
Allopurinol (Systemic) | Allopurinol | Musculoskeletal and Joint Diseases | 13 |
|
Capsaicin 179mg cutaneous patches
1003020AAAAADAD
|
Capsaicin | Capsaicin | Musculoskeletal and Joint Diseases | 13 |
|
Ibuleve Max Strength Pain Relief 10% Gel
1003020P0BCALAI
|
Ibuleve | Ibuprofen | Musculoskeletal and Joint Diseases | 13 |
|
Mobiflex 20mg tablets
100101040BBAAAA
|
Mobiflex | Tenoxicam | Musculoskeletal and Joint Diseases | 13 |
|
Naproxen 125mg/5ml oral suspension
1001010P0AAARAR
|
Naproxen | Naproxen | Musculoskeletal and Joint Diseases | 13 |
|
Salonpas Pain Relief Patch 105mg/31.5mg medicated plasters
1003020AEBBAAAA
|
Salonpas | Methyl salicylate/levomenthol | Musculoskeletal and Joint Diseases | 13 |
|
Methotrexate 2.5mg/5ml oral liquid
1001030U0AAAEAE
|
Methotrexate (Rheumatism) | Methotrexate | Musculoskeletal and Joint Diseases | 12 |
|
Nurofen Express 256mg tablets
1001010APBBAAAA
|
Nurofen express (Ibuprofen sodium dihydrate) | Ibuprofen sodium dihydrate | Musculoskeletal and Joint Diseases | 12 |
|
Phenylbutazone 100mg tablets
1001010Q0AAABAB
|
Phenylbutazone | Phenylbutazone | Musculoskeletal and Joint Diseases | 12 |
|
Glucosamine hydrochloride 500mg / Chondroitin 400mg chew tab
1001050A0AAADAD
|
Glucosamine hydrochloride | Glucosamine hydrochloride (Rheumatic) | Musculoskeletal and Joint Diseases | 10 |
|
Ibuleve Speed Relief 5% gel
1003020P0BCAGAC
|
Ibuleve | Ibuprofen | Musculoskeletal and Joint Diseases | 10 |
|
Methotrexate 10mg/5ml oral liquid
1001030U0AAAHAH
|
Methotrexate (Rheumatism) | Methotrexate | Musculoskeletal and Joint Diseases | 10 |
|
Baclofen 20mg/5ml oral liquid
1002020C0AABDBD
|
Baclofen | Baclofen | Musculoskeletal and Joint Diseases | 9 |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.